Kimlin Tam Ashing

Dr. Kimlin Tam Ashing

Auto-generated profile, based on publicly available information

Dr. Kimlin Tam Ashing


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BABarbara L. Andersen
Barbara L. Andersen
CLChristina Lacchetti
Christina Lacchetti
KAKimlin Ashing
Kimlin Ashing
JBJonathan S. Berek
Jonathan S. Berek
BBBarry S. Berman
Barry S. Berman
JRJulia H. Rowland
Julia H. Rowland
PURPOSE: To update the American Society of Clinical Oncology guideline on the management of anxiety and depression in adult cancer survivors.METHODS: A multidisciplinary expert panel convened to update the guideline. A systematic review of evidence published from 2013-2021 was conducted.RESULTS: The evidence base consisted of 17 systematic reviews ± meta analyses (nine for psychosocial interventions, four for physical exercise, three for mindfulness-based stress reduction [MBSR], and one for pharmacologic interventions), and an additional 44 randomized controlled trials. Psychological, educational, and psychosocial interventions led to improvements in depression and anxiety. Evidence for pharmacologic management of depression and anxiety in cancer survivors was inconsistent. The lack of inclusion of survivors from minoritized groups was noted and identified as an important consideration to provide high-quality care for ethnic minority populations.RECOMMENDATIONS: It is recommended to use a stepped-care model, that is, provide the most effective and least resource-intensive intervention based on symptom severity. All oncology patients should be offered education regarding depression and anxiety. For patients with moderate symptoms of depression, clinicians should offer cognitive behavior therapy (CBT), behavioral activation (BA), MBSR, structured physical activity, or empirically supported psychosocial interventions. For patients with moderate symptoms of anxiety, clinicians should offer CBT, BA, structured physical activity, acceptance and commitment therapy, or psychosocial interventions. For patients with severe symptoms of depression or anxiety, clinicians should offer cognitive therapy, BA, CBT, MBSR, or interpersonal therapy. Treating clinicians may offer a pharmacologic regimen for depression or anxiety for patients who do not have access to first-line treatment, prefer pharmacotherapy, have previously responded well to pharmacotherapy, or have not improved following first-line psychological or behavioral management. Additional information is available at www.asco.org/survivorship-guidelines .

8 March 2012 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
XWXiwei Wu
Xiwei Wu
GSGeorge Somlo
George Somlo
YYYang Yu
Yang Yu
MPMelanie R Palomares
Melanie R Palomares
ALArthur Xuejun Li
Arthur Xuejun Li
Shizhen (Emily) WangShizhen (Emily) Wang
Shizhen (Emily) Wang
Background: MicroRNAs (miRNAs) have been recently detected in the circulation of cancer patients, where they are associated with clinical parameters. Discovery profiling of circulating small RNAs has not been reported in breast cancer (BC), and was carried out in this study to identify blood-based small RNA markers of BC clinical outcome.Methods: The pre-treatment sera of 42 stage II-III locally advanced and inflammatory BC patients who received neoadjuvant chemotherapy (NCT) followed by surgical tumor resection were analyzed for marker identification by deep sequencing all circulating small RNAs. An independent validation cohort of 26 stage II-III BC patients was used to assess the power of identified miRNA markers.Results: More than 800 miRNA species were detected in the circulation, and observed patterns showed association with histopathological profiles of BC. Groups of circulating miRNAs differentially associated with ER/PR/HER2 status and inflammatory BC were identified. The relative levels of selected miRNAs measured by PCR showed consistency with their abundance determined by deep sequencing. Two circulating miRNAs, miR-375 and miR-122, exhibited strong correlations with clinical outcomes, including NCT response and relapse with metastatic disease. In the validation cohort, higher levels of circulating miR-122 specifically predicted metastatic recurrence in stage II-III BC patients.Conclusions: Our study indicates that certain miRNAs can serve as potential blood-based biomarkers for NCT response, and that miR-122 prevalence in the circulation predicts BC metastasis in early-stage patients. These results may allow optimized chemotherapy treatments and preventive anti-metastasis interventions in future clinical applications.

1 November 2006 in Journal of Psychosocial Oncology
Verified
Journal Article
Closed access
KAKimlin T. Ashing-Giwa
Kimlin T. Ashing-Giwa
GPGeraldine V. Padilla
Geraldine V. Padilla
DBDianne E. Bohorquez
Dianne E. Bohorquez
JTJudith S. Tejero
Judith S. Tejero
MGManuela Garcia
Manuela Garcia
MPMph
Mph
Qualitative interviews were used to investigate the impact of breast cancer among Latina survivors. The findings revealed that Latina survivors were optimistic about their health, utilized cultural and religious recovery practices; and seemed to accept their diagnosis, fears and suffering as part of their personal journey. The survivors' narrative identified spirituality as central to their recovery and coping. Extended family and friends were the primary sources of support. Common issues were the impact of cancer on medical care problems, work concerns, the meaning of cancer, family well-being, emotional well-being, body image, and sexual health. Latina survivors, particularly those who are poor and speak limited English, often have inadequate insurance, receive unsatisfactory medical care, and experience poor physician-patient communication and relationship. These problems are directly related to health-care system factors as well as socio-ecological and language issues. In addition, many Latin...

6 February 2007 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
KAKimlin T. Ashing-Giwa
Kimlin T. Ashing-Giwa
JTJudith S. Tejero
Judith S. Tejero
JKJinsook Kim
Jinsook Kim
GPGeraldine V. Padilla
Geraldine V. Padilla
GHGerhard Hellemann
Gerhard Hellemann

1 January 2009 in Oncology Nursing Forum
Verified
Journal Article
Closed access
PDF file
KAKimlin T. Ashing-Giwa
Kimlin T. Ashing-Giwa
JLJung-Won Lim
Jung-Won Lim
To examine how physical and mental health quality of life (QOL) varies in relation to the socioeconomic status and ethnicity among breast cancer survivors; to determine key socioecologic factors influencing outcomes. Cross-sectional. Participants were recruited from the California Cancer Surveillance Program, from hospital registries, and from community agencies in southern California. 703 multiethnic population-based breast cancer survivors, including European, African, Latina, and Asian Americans. Participants completed a mailed questionnaire or answered a telephone survey. To identify socioeconomic status and socioecologic stress, four measures were used: household income, education, job type, and the Life Stress Scale. Physical and mental health QOL, socioeconomic status (income, education, and job type), and socioecologic stress. After controlling for the demographic and medical information, health-related QOL was significantly correlated to socioeconomic status, such that higher socioeconomic status groups expressed better QOL. Ethnic variations existed in QOL according to socioeconomic status. Socioecologic stress was the most important factor influencing physical and mental health QOL. The findings provide additional evidence that low socioeconomic status and high socioecologic stress exacerbate negative QOL sequelae. Practice and research implications include the need for greater attention to QOL outcomes among at-risk lower socioeconomic status survivors and the recognition of the unique contributions of socioeconomic status, socioecologic stress, and ethnicity on physical and mental health QOL.

21 April 2010 in Cancer
Verified
Journal Article
Open access
PDF file
KAKimlin T. Ashing‐Giwa
Kimlin T. Ashing‐Giwa
PGPatricia Gonzalez
Patricia Gonzalez
JLJung‐Won Lim
Jung‐Won Lim
CCCathie Chung
Cathie Chung
BPBenjamin Paz
Benjamin Paz
MWMark T. Wakabayashi
Mark T. Wakabayashi
BACKGROUND: Several publications reporting on health disparities document that ethnic minorities disproportionately experience delays in healthcare access, delivery, and treatment. However, few studies examine factors underlying access and receipt of healthcare among cancer survivors from the patient perspective. This study explores diagnostic and therapeutic care delays among a multiethnic sample of breast and cervical cancer survivors and examines contextual factors influencing diagnostic and therapeutic care delays.METHODS: Population‐based sampling and a cross‐sectional design were used to recruit 1377 survivors (breast cancer, n = 698; cervical cancer, n = 679). This multiethnic sample included 449 European American, 185 African American, 468 Latina American, and 275 Asian American survivors.RESULTS: Latina Americans were more likely to report diagnostic delays (P = .003), whereas African Americans were more likely to report therapeutic delays (P = .007). In terms of cancer type, cervical cancer survivors were more likely to report diagnostic (P = .004) and therapeutic delays (P = .000) compared with breast cancer survivors. “Fear of finding cancer” was the most frequently cited reason for diagnostic delays, and “medical reasons” were most frequently cited for therapeutic delays.CONCLUSIONS: Due in part to a higher proportion of diagnostic and therapeutic delays, ethnic minorities endure greater cancer burden, including poorer survival and survivorship outcomes. The medical community must recognize the impact of existing psychological and cultural dimensions on diagnostic care, as well as the personal and healthcare system level barriers that contribute to therapeutic delays. Cancer 2010. © 2010 American Cancer Society.